p53-Dependent p21 mRNA Elongation Is Impaired when DNA Replication Is Stalled

REFERENCES

• An, W., J. Kim, and R. G. Roeder. 2004. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117:735–748.
   PubMed Web of Science ®Google Scholar
• Appella, E., and C. W. Anderson. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764–2772.
   PubMedGoogle Scholar
• Ard, P. G., C. Chatterjee, S. Kunjibettu, L. R. Adside, L. E. Gralinski, and S. B. McMahon. 2002. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol. Cell. Biol. 22:5650–5661.
   PubMed Web of Science ®Google Scholar
• Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468.
   PubMed Web of Science ®Google Scholar
• Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8:1243–1254.
   PubMed Web of Science ®Google Scholar
• Bartek, J., C. Lukas, and J. Lukas. 2004. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5:792–804.
   PubMed Web of Science ®Google Scholar
• Berger, S. L. 2002. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12:142–148.
   PubMed Web of Science ®Google Scholar
• Bronder, J. L., and R. G. Moran. 2003. A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J. Biol. Chem. 278:48861–48871.
   PubMed Web of Science ®Google Scholar
• Brooks, C. L., and W. Gu. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164–171.
   PubMed Web of Science ®Google Scholar
• Chen, X., G. Farmer, H. Zhu, R. Prywes, and C. Prives. 1993. Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation. Genes Dev. 7:1837–1849.
   PubMedGoogle Scholar
• Chipuk, J. E., L. Bouchier-Hayes, T. Kuwana, D. D. Newmeyer, and D. R. Green. 2005. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309:1732–1735.
   PubMed Web of Science ®Google Scholar
• Chipuk, J. E., T. Kuwana, L. Bouchier-Hayes, N. M. Droin, D. D. Newmeyer, M. Schuler, and D. R. Green. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010–1014.
   PubMed Web of Science ®Google Scholar
• Chuikov, S., J. K. Kurash, J. R. Wilson, B. Xiao, N. Justin, G. S. Ivanov, K. McKinney, P. Tempst, C. Prives, S. J. Gamblin, N. A. Barlev, and D. Reinberg. 2004. Regulation of p53 activity through lysine methylation. Nature 432:353–360.
   PubMed Web of Science ®Google Scholar
• Claudio, P. P., J. Cui, M. Ghafouri, C. Mariano, M. K. White, M. Safak, J. B. Sheffield, A. Giordano, K. Khalili, S. Amini, and B. E. Sawaya. 2006. Cdk9 phosphorylates p53 on serine 392 independently of CKII. J. Cell. Physiol. 208:602–612.
   PubMed Web of Science ®Google Scholar
• Coutts, A. S., and N. B. La Thangue. 2005. The p53 response: emerging levels of co-factor complexity. Biochem. Biophys. Res. Commun. 331:778–785.
   PubMed Web of Science ®Google Scholar
• Dumont, P., J. I. Leu, A. C. Della Pietra III, D. L. George, and M. Murphy. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33:357–365.
   PubMed Web of Science ®Google Scholar
• Dvir, A., J. W. Conaway, and R. C. Conaway. 2001. Mechanism of transcription initiation and promoter escape by RNA polymerase II. Curr. Opin. Genet. Dev. 11:209–214.
   PubMedGoogle Scholar
• Dvir, A., R. C. Conaway, and J. W. Conaway. 1997. A role for TFIIH in controlling the activity of early RNA polymerase II elongation complexes. Proc. Natl. Acad. Sci. USA 94:9006–9010.
   PubMedGoogle Scholar
• Ehrenhofer-Murray, A. E. 2004. Chromatin dynamics at DNA replication, transcription and repair. Eur. J. Biochem. 271:2335–2349.
   PubMedGoogle Scholar
• Eick, D., F. Kohlhuber, D. A. Wolf, and L. J. Strobl. 1994. Activation of pausing RNA polymerases by nuclear run-on experiments. Anal. Biochem. 218:347–351.
   PubMedGoogle Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57–69.
   PubMed Web of Science ®Google Scholar
• Espinosa, J. M., R. E. Verdun, and B. M. Emerson. 2003. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 12:1015–1027.
   PubMed Web of Science ®Google Scholar
• Felsenfeld, G., and M. Groudine. 2003. Controlling the double helix. Nature 421:448–453.
   PubMed Web of Science ®Google Scholar
• Giaccia, A. J., and M. B. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:2973–2983.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M. 2003. Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Semin. Hematol. 40:10–17.
   PubMedGoogle Scholar
• Gomes, N. P., G. Bjerke, B. Llorente, S. A. Szostek, B. M. Emerson, and J. M. Espinosa. 2006. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 20:601–612.
   PubMed Web of Science ®Google Scholar
• Goodrich, J. A., and R. Tjian. 1994. Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell 77:145–156.
   PubMedGoogle Scholar
• Gottifredi, V., O. Karni-Schmidt, S. S. Shieh, and C. Prives. 2001. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol. Cell. Biol. 21:1066–1076.
   PubMed Web of Science ®Google Scholar
• Gottifredi, V., K. McKinney, M. V. Poyurovsky, and C. Prives. 2004. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J. Biol. Chem. 279:5802–5810.
   PubMedGoogle Scholar
• Gottifredi, V., and C. Prives. 2005. The S phase checkpoint: when the crowd meets at the fork. Semin. Cell Dev. Biol. 16:355–368.
   PubMedGoogle Scholar
• Gottifredi, V., S. Shieh, Y. Taya, and C. Prives. 2001. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl. Acad. Sci. USA 98:1036–1041.
   PubMed Web of Science ®Google Scholar
• Hainaut, P., and M. Hollstein. 2000. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:81–137.
   PubMed Web of Science ®Google Scholar
• Hammond, E. M., N. C. Denko, M. J. Dorie, R. T. Abraham, and A. J. Giaccia. 2002. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22:1834–1843.
   PubMed Web of Science ®Google Scholar
• Hammond, E. M., D. J. Mandell, A. Salim, A. J. Krieg, T. M. Johnson, H. A. Shirazi, L. D. Attardi, and A. J. Giaccia. 2006. Genome-wide analysis of p53 under hypoxic conditions. Mol. Cell. Biol. 26:3492–3504.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
   PubMed Web of Science ®Google Scholar
• Jin, Z., and W. S. El-Deiry. 2005. Overview of cell death signaling pathways. Cancer Biol. Ther. 4:139–163.
   PubMed Web of Science ®Google Scholar
• Kaeser, M. D., and R. D. Iggo. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99:95–100.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Kessis, T. D., R. J. Slebos, W. G. Nelson, M. B. Kastan, B. S. Plunkett, S. M. Han, A. T. Lorincz, L. Hedrick, and K. R. Cho. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988–3992.
   PubMed Web of Science ®Google Scholar
• Kim, J., S. B. Hake, and R. G. Roeder. 2005. The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol. Cell 20:759–770.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., S. Y. Shieh, X. Chen, L. Jayaraman, K. Tamai, Y. Taya, C. Prives, and Z. Q. Pan. 1997. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol. Cell. Biol. 17:7220–7229.
   PubMed Web of Science ®Google Scholar
• Komarnitsky, P., E. J. Cho, and S. Buratowski. 2000. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev. 14:2452–2460.
   PubMed Web of Science ®Google Scholar
• Koumenis, C., R. Alarcon, E. Hammond, P. Sutphin, W. Hoffman, M. Murphy, J. Derr, Y. Taya, S. W. Lowe, M. Kastan, and A. Giaccia. 2001. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell. Biol. 21:1297–1310.
   PubMed Web of Science ®Google Scholar
• Laurent, G., and J. P. Jaffrezou. 2001. Signaling pathways activated by daunorubicin. Blood 98:913–924.
   PubMed Web of Science ®Google Scholar
• Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J. M. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 15:1615–1624.
   PubMedGoogle Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Levine, A. J., W. Hu, and Z. Feng. 2006. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13:1027–1036.
   PubMed Web of Science ®Google Scholar
• Liu, X., C. W. Miller, P. H. Koeffler, and A. J. Berk. 1993. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13:3291–3300.
   PubMedGoogle Scholar
• Ljungman, M., F. Zhang, F. Chen, A. J. Rainbow, and B. C. McKay. 1999. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18:583–592.
   PubMed Web of Science ®Google Scholar
• McKinney, K., M. Mattia, V. Gottifredi, and C. Prives. 2004. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16:413–424.
   PubMedGoogle Scholar
• Mihara, M., S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, and U. M. Moll. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11:577–590.
   PubMed Web of Science ®Google Scholar
• Murray, E. J. 1991. Gene transfer and expression protocols. Humana Press, Clifton, NJ.
   Google Scholar
• Nayak, B. K., and G. M. Das. 2002. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene 21:7226–7229.
   PubMed Web of Science ®Google Scholar
• Nguyen, T. T., K. Cho, S. A. Stratton, and M. C. Barton. 2005. Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene. Mol. Cell. Biol. 25:2147–2157.
   PubMedGoogle Scholar
• Oren, M. 2003. Decision making by p53: life, death and cancer. Cell Death Differ. 10:431–442.
   PubMed Web of Science ®Google Scholar
• Pluquet, O., and P. Hainaut. 2001. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174:1–15.
   PubMed Web of Science ®Google Scholar
• Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112–126.
   PubMed Web of Science ®Google Scholar
• Prives, C., and J. L. Manley. 2001. Why is p53 acetylated? Cell 107:815–818.
   PubMed Web of Science ®Google Scholar
• Scheffner, M., and N. J. Whitaker. 2003. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin. Cancer Biol. 13:59–67.
   PubMed Web of Science ®Google Scholar
• Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89:12028–12032.
   PubMed Web of Science ®Google Scholar
• Shinobu, N., T. Maeda, T. Aso, T. Ito, T. Kondo, K. Koike, and M. Hatakeyama. 1999. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J. Biol. Chem. 274:17003–17010.
   PubMedGoogle Scholar
• Sigal, A., and V. Rotter. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60:6788–6793.
   PubMed Web of Science ®Google Scholar
• Sims, R. J., III, R. Belotserkovskaya, and D. Reinberg. 2004. Elongation by RNA polymerase II: the short and long of it. Genes Dev. 18:2437–2468.
   PubMed Web of Science ®Google Scholar
• Skoog, L., and B. Nordenskjold. 1971. Effects of hydroxyurea and 1-beta-d-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells. Eur. J. Biochem. 19:81–89.
   PubMedGoogle Scholar
• Sobell, H. M. 1985. Actinomycin and DNA transcription. Proc. Natl. Acad. Sci. USA 82:5328–5331.
   PubMed Web of Science ®Google Scholar
• Szak, S. T., D. Mays, and J. A. Pietenpol. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21:3375–3386.
   PubMed Web of Science ®Google Scholar
• Thirman, M. J., D. A. Levitan, H. Kobayashi, M. C. Simon, and J. D. Rowley. 1994. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 91:12110–12114.
   PubMed Web of Science ®Google Scholar
• Timson, J. 1975. Hydroxyurea. Mutat. Res. 32:115–132.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307–310.
   PubMed Web of Science ®Google Scholar
• Vousden, K. H., and X. Lu. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594–604.
   PubMed Web of Science ®Google Scholar
• Wei, C. L., Q. Wu, V. B. Vega, K. P. Chiu, P. Ng, T. Zhang, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, J. Liu, X. D. Zhao, J. L. Chew, Y. L. Lee, V. A. Kuznetsov, W. K. Sung, L. D. Miller, B. Lim, E. T. Liu, Q. Yu, H. H. Ng, and Y. Ruan. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207–219.
   PubMed Web of Science ®Google Scholar
• Wiederschain, D., H. Kawai, A. Shilatifard, and Z. M. Yuan. 2005. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J. Biol. Chem. 280:24315–24321.
   PubMedGoogle Scholar
• Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132.
   PubMed Web of Science ®Google Scholar
• Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, C. J. Ingles, et al. 1994. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol. 14:7013–7024.
   PubMed Web of Science ®Google Scholar
• Zhan, Q., M. J. Antinore, X. W. Wang, F. Carrier, M. L. Smith, C. C. Harris, and A. J. Fornace, Jr. 1999. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18:2892–2900.
   PubMed Web of Science ®Google Scholar